Do highly concentrated gadolinium chelates improve MR brain perfusion imaging? Intraindividually controlled randomized crossover concentration comparison study of 0.5 versus 1.0 mol/L gadobutrol

Radiology

Volumn 226, Issue 3, 2003, Pages 880-888

  Tombach, Bernd ^a   Benner, Thomas ^b   Reimer, Peter ^c   Schuierer, Gerhard ^d   Fallenberg, Eva Maria ^a   Geens, Viviane ^e   Wels, Thomas ^e   Sorensen, A Gregory ^b  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF FREIBURG   (Germany)

^d Institute of Neuroradiology   (Germany)

^e NONE

Author keywords

Brain; Comparative studies Gadolinium Magnetic resonance (MR); Contrast media

Indexed keywords

GADOBUTROL; GADOLINIUM CHELATE;

ADULT; ARTICLE; BRAIN BLOOD FLOW; BRAIN PERFUSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; FEMALE; GRAY MATTER; HUMAN; HUMAN EXPERIMENT; IMAGE QUALITY; MALE; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SIGNAL NOISE RATIO; WHITE MATTER;

ADULT; ANALYSIS OF VARIANCE; BRAIN MAPPING; CONTRAST MEDIA; CROSS-OVER STUDIES; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS;

EID: 0037370058     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiol.2263011970     Document Type: Article

References (32)

1. Villringer A, Rosen BR, Belliveau JW, et al. Dynamic imaging with lanthanides chelates in normal brain: contrast due to magnetic susceptibility effects. Magn Reson Med 1988; 6:164-174.
2. Fisel CR, Ackerman JL, Buxton RB, et al. MR contrast due to microscopically heterogeneous magnetic susceptibility: numerical simulations and applications to cerebral physiology. Magn Reson Med 1991; 17:336-347.
3. Majumdar S, Zoghbi SS, Gore JC. Regional differences in rat brain displayed by fast MRI with superparamagnetic contrasts agents. Magn Reson Imaging 1988; 6:611-615.
4. Hardy PA, Henkelman RM. Transverse relaxation rate enhancement caused by magnetic particulates. Magn Reson Imaging 1989; 7(3):265-275.
5. Ostergaard L, Weisskopf RM, Chesler DA, Gyldensted C, Rosen BR. High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. I. Mathematical approach and statistical analysis. Magn Reson Med 1996; 36:715-725.
6. Ostergaard L, Sorensen AG, Kwong KK, Weisskopf RM, Gyldensted C, Rosen BR. High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. II. Experimental design and preliminary results. Magn Reson Med 1 1996; 36:726-736.
7. Boxerman JL, Rosen BR, Weisskopf RM. Signal-to-noise analysis of cerebral blood volume maps from dynamic NMR imaging studies. J Magn Reson Imaging 1997; 7:528-537.
8. Heiland S, Benner T, Reith W, Forsting M, Sartor K. Perfusion-weighted MRI using gadobutrol as a contrast agent in a rat stroke model. J Magn Reson Imaging 1997; 7:1109-1115.
9. Barbier EL, Lamalle L, Decorps M. Methodology of brain perfusion imaging. J Magn Reson Imaging 2001; 13:496-520.
10. Sorensen AG, Reimer P. Cerebral MR perfusion imaging: principles and current applications. Stuttgart, Germany: Georg Thieme Verlag, 2000.
11. Rosen BR, Belliveau JB, Chien D. Perfusion imaging by nuclear magnetic resonance. Magn Reson Q 1989; 5:263-281.
12. Rosen B, Belliveau J, Vevea J, Brady T. Perfusion imaging with NMR contrast agents. Magn Reson Med 1990; 14:249-266.
13. Boxerman JL, Hamberg LM, Rosen BR, Weisskopf RM. MR contrast due to intravascular magnetic susceptibility perturbations. Magn Reson Med 1995; 34:555-566.
14. Vogler H, Platzek J, Schuhmann-Giampieri G, et al. Pre-clinical evaluation of gadobutrol: a new, neutral, extracellular contrast agent for magnetic resonance imaging. EurJ Radiol 1995; 21:1-10.
15. Staks T, Schumann-Giampieri G, Frenzel T, Weinmann HJ, Lange L, Platzek J. Pharmacokinetics, dose proportionality, and tolerability of gadobutrol after single intravenous injection in healthy volunteers. Invest Radiol 1994; 29:709-715.
16. Muhler A. Assessment of myocardial perfusion using contrast-enhanced MR imaging: current status and future developments. MAGMA 1995; 3:21-33.
17. Muhler A, Weinmann HJ. Arterial concentrations following intravenous bolus injection of gadobutrol: comparison of 0.5 and 1.0 molar stock solutions (abstr). In: Proceedings of the Society of Magnetic Resonance in Medicine and the European Society of Magnetic Resonance in Medicine and Biology. Berkeley, Calif: Society of Magnetic Resonance in Medicine, 1995; 1128.
18. Heiland S, Benner T, Reith W, Forsting M, Sartor K. Does higher contrast agent dosage and concentration enhance the reliability of perfusion-weighted MRI? A computer simulation (abstr). In: Proceedings of the Fifth Meeting of the International Society for Magnetic Resonance in Medicine. Berkeley, Calif: International Society for Magnetic Resonance in Medicine, 1997; 1782.
19. Tombach B, Bremer C, Reimer P, et al. Renal tolerance of a neutral gadolinium chelate (gadobutrol) in patients with chronic renal failure: results of a randomized study. Radiology 2001; 218:651-657.
20. Weinmann HJ, Platzek J, Raduchel B, Schumann-Giampieri G, Vogler H. A new macrocyclic gadolinium chelate as a contrast agent for MRI. Eur Radiol 1993; 3(suppl):126.
21. Aronen HJ, Gazit IE, Louis DN, et al. Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology 1994; 191:41-51.
22. Aronen HJ, Boxerman JL, Goldberg IE, et al. Susceptibility-contrast CBV imaging: optimization of contrast dose and imaging sequences (abstr). In: Book of abstracts: Society of Magnetic Resonance in Medicine 1992. Berkeley, Calif: Society of Magnetic Resonance in Medicine, 1992; 1129.
23. Moonen CTW, Liu G, van Gelderen P, Sobering G. A fast gradient-recalled MRI technique with increased sensitivity to dynamic susceptibility effects. Magn Reson Med 1992; 26:184-189.
24. Sorensen AG, Tievsky AL, Ostergaard L, Weisskoff RM, Rosen BR. Contrast agents in functional MR imaging. J Magn Reson Imaging 1997; 7:47-55.
25. Roberts TPL, Chuang N, Roberts HC. Neuroimaging: do we really need new contrast agents for MRI? Eur J Radiol 2000; 34:166-178.
26. Edelman RR, Mattle HP, Atkinson DJ, et al. Cerebral blood flow: assessment with dynamic contrast enhanced T2-weighted MR imaging at 1.5 T. Radiology 1990; 176:211-220.
27. Runge VM, Kirsch JE, Wells JW, Woolfolk CE. Assessment of cerebral perfusion by first-pass, dynamic contrast-enhanced, steady-state free precession MR imaging: an animal study. AJR Am J Roentgenol 1993; 160:593-600.
28. Jones RA, Haraldseth O, Müller TB, Rinck PA, Oksendal AN. K-space substitution: a novel dynamic imaging technique. Magn Reson Med 1993; 29:830-834.
29. Claussen CD, Banzer D, Pfretzschner C, Kalender WA, Schörner W. Bolus geometry and dynamics after intravenous contrast medium injection. Radiology 1984; 153:365-368.
30. Reith W, Heiland S, Erb G, Benner T, Forsting M, Sartor K. Dynamic contrast-enhanced T2*-weighted MRI in patients with cerebrovascular disease. Neuroradiology 1997; 39:250-257.
31. Neumann-Haefelin T, Wittsack HJ, Wenserski F, et al. Diffusion- and perfusion-weighted MRI: the DWI/PWI mismatch region in acute stroke. Stroke 1999; 30:1591-1597.
32. Benner T, Reimer P, Erb G, et al. Cerebral MR perfusion imaging: first clinical application of a 1 M gadolinium chelate (Gadovist 1.0) in a double-blinded randomized dose-finding study. J Magn Reson Imaging 2000; 12:371-380.